This site is intended for healthcare professionals

Omeros Corporation submits its BLA to the FDA for narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Read time: 1 mins
Last updated:19th Nov 2020
Published:19th Nov 2020
Condition: Thrombotic Microangiopathies /HSCT- TMA
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest